Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Isotechnika Pharma Inc IPHAF

Healthcare Biotechnology


GREY:IPHAF - Post by User

Isotechnika Pharma Inc
Bullboard Posts
User Avatar Image
(0)
•••
Comment by stockman6on May 14, 2002 5:59pm
172 Views
Post# 5111215

RE: this day in history - jak

RE: this day in history - jak"Anyone care to guess where the stock might be in three more months based on altius' crystal ball?" OK, I have no idea why, but I'll bite. Based on your post, when the price was at $3.50, Altius guessed that there would be a 57% price decline to $1.50. The price actually climbed 44% from that time. She is now pridicting a 21% decline from $5.06, therefore the price, assuming the same time periods are used, the same trend occurs, etc., etc., should move up 16% to $5.88 by the next quarter. I AM 100% CERTAIN OF THIS!!!!
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities